Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

1.

Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.

French AJ, Sargent DJ, Burgart LJ, Foster NR, Kabat BF, Goldberg R, Shepherd L, Windschitl HE, Thibodeau SN.

Clin Cancer Res. 2008 Jun 1;14(11):3408-15. doi: 10.1158/1078-0432.CCR-07-1489.

PMID:
18519771
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, Gallinger S, Sargent DJ.

J Natl Cancer Inst. 2011 Jun 8;103(11):863-75. doi: 10.1093/jnci/djr153. Epub 2011 May 19. Erratum in: J Natl Cancer Inst. 2011 Nov 2;103(21):1639. Kim, George P [added].

PMID:
21597022
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy.

Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, Nelson GD, Goldberg RM, Sargent DJ, Alberts SR.

J Clin Oncol. 2013 Oct 10;31(29):3664-72. doi: 10.1200/JCO.2013.48.9591. Epub 2013 Sep 9.

PMID:
24019539
[PubMed - indexed for MEDLINE]
4.

BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.

Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, Shadrach B, Pai RK.

Am J Surg Pathol. 2012 May;36(5):744-52. doi: 10.1097/PAS.0b013e31824430d7.

PMID:
22314188
[PubMed - indexed for MEDLINE]
5.

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, Richman S, Chambers P, Seymour M, Kerr D, Gray R, Quirke P.

J Clin Oncol. 2011 Apr 1;29(10):1261-70. doi: 10.1200/JCO.2010.30.1366. Epub 2011 Mar 7. Erratum in: J Clin Oncol. 2011 Jul 20;29(21):2949.

PMID:
21383284
[PubMed - indexed for MEDLINE]
6.

Association of obesity with DNA mismatch repair status and clinical outcome in patients with stage II or III colon carcinoma participating in NCCTG and NSABP adjuvant chemotherapy trials.

Sinicrope FA, Foster NR, Yoon HH, Smyrk TC, Kim GP, Allegra CJ, Yothers G, Nikcevich DA, Sargent DJ.

J Clin Oncol. 2012 Feb 1;30(4):406-12. doi: 10.1200/JCO.2011.39.2563. Epub 2011 Dec 27.

PMID:
22203756
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, Ribic C, Grothey A, Moore M, Zaniboni A, Seitz JF, Sinicrope F, Gallinger S.

J Clin Oncol. 2010 Jul 10;28(20):3219-26. doi: 10.1200/JCO.2009.27.1825. Epub 2010 May 24. Erratum in: J Clin Oncol. 2010 Oct 20;28(30):4664.

PMID:
20498393
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803.

Ogino S, Shima K, Meyerhardt JA, McCleary NJ, Ng K, Hollis D, Saltz LB, Mayer RJ, Schaefer P, Whittom R, Hantel A, Benson AB 3rd, Spiegelman D, Goldberg RM, Bertagnolli MM, Fuchs CS.

Clin Cancer Res. 2012 Feb 1;18(3):890-900. doi: 10.1158/1078-0432.CCR-11-2246. Epub 2011 Dec 6.

PMID:
22147942
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Association between deficient mismatch repair system and efficacy to irinotecan-containing chemotherapy in metastatic colon cancer.

Kim JE, Hong YS, Ryu MH, Lee JL, Chang HM, Lim SB, Kim JH, Jang SJ, Kim MJ, Yu CS, Kang YK, Kim JC, Kim TW.

Cancer Sci. 2011 Sep;102(9):1706-11. doi: 10.1111/j.1349-7006.2011.02009.x. Epub 2011 Jul 12.

PMID:
21679278
[PubMed - indexed for MEDLINE]
10.

The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients.

Fariña-Sarasqueta A, van Lijnschoten G, Moerland E, Creemers GJ, Lemmens VE, Rutten HJ, van den Brule AJ.

Ann Oncol. 2010 Dec;21(12):2396-402. doi: 10.1093/annonc/mdq258. Epub 2010 May 25.

PMID:
20501503
[PubMed - indexed for MEDLINE]
Free Article
11.

Management of stage II colon cancer - the use of molecular biomarkers for adjuvant therapy decision.

Donada M, Bonin S, Barbazza R, Pettirosso D, Stanta G.

BMC Gastroenterol. 2013 Feb 27;13:36. doi: 10.1186/1471-230X-13-36.

PMID:
23446022
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.

Zaanan A, Fléjou JF, Emile JF, Des GG, Cuilliere-Dartigues P, Malka D, Lecaille C, Validire P, Louvet C, Rougier P, de Gramont A, Bonnetain F, Praz F, Taïeb J.

Clin Cancer Res. 2011 Dec 1;17(23):7470-8. doi: 10.1158/1078-0432.CCR-11-1048. Epub 2011 Oct 13.

PMID:
21998335
[PubMed - indexed for MEDLINE]
Free Article
13.

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F.

J Clin Oncol. 2010 Jan 20;28(3):466-74. doi: 10.1200/JCO.2009.23.3452. Epub 2009 Dec 14.

PMID:
20008640
[PubMed - indexed for MEDLINE]
14.

Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors.

Honecker F, Wermann H, Mayer F, Gillis AJ, Stoop H, van Gurp RJ, Oechsle K, Steyerberg E, Hartmann JT, Dinjens WN, Oosterhuis JW, Bokemeyer C, Looijenga LH.

J Clin Oncol. 2009 May 1;27(13):2129-36. doi: 10.1200/JCO.2008.18.8623. Epub 2009 Mar 16.

PMID:
19289622
[PubMed - indexed for MEDLINE]
15.

Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation.

Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, Burgess AW, Croxford M, Jones I, Langland R, Kosmider S, McKay D, Bollag G, Nolop K, Sieber OM, Desai J.

Int J Cancer. 2011 May 1;128(9):2075-84. doi: 10.1002/ijc.25555.

PMID:
20635392
[PubMed - indexed for MEDLINE]
16.

Integrated analysis of molecular and clinical prognostic factors in stage II/III colon cancer.

Roth AD, Delorenzi M, Tejpar S, Yan P, Klingbiel D, Fiocca R, d'Ario G, Cisar L, Labianca R, Cunningham D, Nordlinger B, Bosman F, Van Cutsem E.

J Natl Cancer Inst. 2012 Nov 7;104(21):1635-46. doi: 10.1093/jnci/djs427. Epub 2012 Oct 25. Erratum in: J Natl Cancer Inst. 2013 Jan 16;105(2):151-2.

PMID:
23104212
[PubMed - indexed for MEDLINE]
Free Article
17.

Prognostic impact of FoxP3+ regulatory T cells in relation to CD8+ T lymphocyte density in human colon carcinomas.

Yoon HH, Orrock JM, Foster NR, Sargent DJ, Smyrk TC, Sinicrope FA.

PLoS One. 2012;7(8):e42274. doi: 10.1371/journal.pone.0042274. Epub 2012 Aug 6.

PMID:
22879926
[PubMed - indexed for MEDLINE]
Free PMC Article
18.

Clinicopathologic factors identify sporadic mismatch repair-defective colon cancers.

Halvarsson B, Anderson H, Domanska K, Lindmark G, Nilbert M.

Am J Clin Pathol. 2008 Feb;129(2):238-44. doi: 10.1309/0PP5GDRTXUDVKAWJ.

PMID:
18208804
[PubMed - indexed for MEDLINE]
Free Article
19.

Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.

Popovici V, Budinska E, Tejpar S, Weinrich S, Estrella H, Hodgson G, Van Cutsem E, Xie T, Bosman FT, Roth AD, Delorenzi M.

J Clin Oncol. 2012 Apr 20;30(12):1288-95. doi: 10.1200/JCO.2011.39.5814. Epub 2012 Mar 5.

PMID:
22393095
[PubMed - indexed for MEDLINE]
20.

Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial.

Ogino S, Liao X, Imamura Y, Yamauchi M, McCleary NJ, Ng K, Niedzwiecki D, Saltz LB, Mayer RJ, Whittom R, Hantel A, Benson AB 3rd, Mowat RB, Spiegelman D, Goldberg RM, Bertagnolli MM, Meyerhardt JA, Fuchs CS; Alliance for Clinical Trials in Oncology.

J Natl Cancer Inst. 2013 Dec 4;105(23):1789-98. doi: 10.1093/jnci/djt298. Epub 2013 Nov 14.

PMID:
24231454
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk